Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): a post hoc subgroup analysis of patients with gastrointestinal cancer

被引:5
|
作者
Harada, Toshiyuki [1 ]
Imai, Hisao [2 ,3 ]
Fumita, Soichi [4 ]
Noriyuki, Toshio [5 ]
Gamoh, Makio [6 ]
Okamoto, Masaharu [7 ]
Akashi, Yusaku [4 ]
Kizawa, Yoshiyuki [8 ]
Tokoro, Akihiro [9 ,10 ]
机构
[1] JCHO Hokkaido Hosp, Ctr Resp Dis, Sapporo, Hokkaido, Japan
[2] Gunma Prefectural Canc Ctr, Div Resp Med, Gunma, Japan
[3] Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Hidaka, Saitama, Japan
[4] Kindai Univ, Dept Med Oncol, Nara Hosp, Nara, Japan
[5] Onomichi Gen Hosp, Dept Surg, Onomichi, Hiroshima, Japan
[6] Osaki Citizen Hosp, Dept Med Oncol, Osaki, Miyagi, Japan
[7] Shionogi & Co Ltd, Med Affairs, Osaka, Japan
[8] Kobe Univ, Grad Sch Med, Dept Palliat Med, Kobe, Hyogo, Japan
[9] Natl Hosp Org Kinki Chuo Chest Med Ctr, Dept Psychosomat Internal Med, Sakai, Osaka, Japan
[10] Natl Hosp Org Kinki Chuo Chest Med Ctr, Support & Palliat Care Team, Osaka, Japan
关键词
Cancer pain; GI cancer; Observational study; Opioid-induced constipation; OIC-J; VALIDATION; MANAGEMENT;
D O I
10.1007/s10147-020-01790-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Constipation is a common side effect of opioid therapy. An observational study of opioid-induced constipation (OIC) in Japanese patients with cancer (OIC-J) included 212 patients with various tumor types. This post hoc analysis of OIC-J evaluated a subgroup of patients with gastrointestinal (GI) cancer. Methods Patients were aged >= 20 years, starting strong opioid therapy, had an ECOG PS of <= 2, and must have had >= 3 bowel movements during the week before enrollment. OIC was evaluated for 2 weeks after opioid initiation using the Rome IV diagnostic criteria for colorectal disorders, as well as physician's diagnosis, number of spontaneous bowel movements, Bowel Function Index score, and patient's self-assessment. Relationships between baseline characteristics and OIC incidence, and the effects of OIC on quality of life (QOL) were also explored. Results Fifty patients from OIC-J who had GI cancer [colon (50%), stomach (28%), and esophageal (22%)] were included. OIC incidence varied by which diagnostic criteria were used (46.0-62.0%) and occurred rapidly after initiating opioid therapy. The use of prophylactic laxatives reduced the overall incidence rate of OIC from 71.0% to 47.4%. No baseline characteristics, except comorbidities, were associated with OIC incidence. Change from baseline to day 15 in PAC-SYM total score was significantly greater for patients with OIC versus those without OIC (0.188 versus -0.362;P = 0.0011). Conclusions This post hoc analysis suggests that OIC occurs rapidly in patients with GI cancer after initiating opioid therapy, and negatively impacts QOL. Early and effective intervention strategies may be particularly useful in this group. Additional Information Coauthor Makio Gamoh is deceased.
引用
收藏
页码:104 / 110
页数:7
相关论文
共 50 条
  • [11] The burden of opioid-induced constipation among patients with cancer pain and patients with non-cancer pain
    LoCasale, R.
    King, F.
    Margolis, M. K.
    Coyne, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S229 - S230
  • [12] Opioid-Induced Constipation in Advanced Cancer Patients
    ALMouaalamy, Nabil
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (04)
  • [13] Opioid-induced constipation among a convenience sample of Patients with cancer Pain
    Coyne, Karin S.
    Sexton, Chris
    LoCasale, Robert J.
    King, Frederic R.
    Margolis, Mary Kay
    Ahmedzai, Sam H.
    FRONTIERS IN ONCOLOGY, 2016, 6
  • [14] Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan
    Takata, Keiko
    Nakazawa, Masami
    Honda, Keiichi
    Hashimoto, Sayo
    SUPPORTIVE CARE IN CANCER, 2022, 30 (05) : 3943 - 3954
  • [15] Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan
    Keiko Takata
    Masami Nakazawa
    Keiichi Honda
    Sayo Hashimoto
    Supportive Care in Cancer, 2022, 30 : 3943 - 3954
  • [16] Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis
    Kanbayashi, Yuko
    Shimizu, Mayumi
    Ishizuka, Yuichi
    Sawa, Shohei
    Yabe, Katsushige
    Uchida, Mayako
    PLOS ONE, 2022, 17 (12):
  • [17] Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan Response
    Koczwara, Bogda
    Deckx, Laura
    Ullah, Shahid
    van den Akker, Marjan
    SUPPORTIVE CARE IN CANCER, 2022, 30 (03) : 1897 - 1897
  • [18] Methylnaltrexone treatment of opioid-induced constipation in cancer patients
    Karver, S. B.
    Slatkin, N. E.
    Thomas, J.
    Israel, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [19] Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation
    Antoine Lemaire
    Yoann Pointreau
    Bérengère Narciso
    François-Xavier Piloquet
    Viorica Braniste
    Jean-Marc Sabaté
    Supportive Care in Cancer, 2021, 29 : 7577 - 7586
  • [20] Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation
    Lemaire, Antoine
    Pointreau, Yoann
    Narciso, Berengere
    Piloquet, Francois-Xavier
    Braniste, Viorica
    Sabate, Jean-Marc
    SUPPORTIVE CARE IN CANCER, 2021, 29 (12) : 7577 - 7586